RxDoctor Payments Data

Wayne Frederick

Surgical Oncology · Washington, DCNPI 1962408252

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $831,743 of the $831,773 with a category attached, or 100.0%. Insulet Corporation accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $314,752 and has fallen 67.4% since, to $102,500 in 2025.

$831,773in general payments, 2019–2025

Across 24 payments — averaging $34,657 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$832K
  • Integra Lifesciences Corporation$30

What the payments were for

  • Speaking & faculty fees$831,743100%
  • Food & beverage$300%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Insulet Corporation23$831,743
Integra Lifesciences Corporation1$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few surgical oncology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Other surgical oncology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →